Rab25 promotes erlotinib resistance by activating the β1 integrin/AKT/β‐catenin pathway in NSCLC

OBJECTIVES: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) has significant therapeutic efficacy in non‐small‐cell lung cancer (NSCLC) patients. However, acquired resistance is inevitable and limits the long‐term efficacy of EGFR‐TKI. Our study aimed to investigate the role of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianmin, Zhou, Pu, Wang, Xudong, Yu, Yongxin, Zhu, Guangkuo, Zheng, Linpeng, Xu, Zihan, Li, Feng, You, Qiai, Yang, Qiao, Zhuo, Wenlei, Sun, Jianguo, Chen, Zhengtang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536583/
https://www.ncbi.nlm.nih.gov/pubmed/30848009
http://dx.doi.org/10.1111/cpr.12592

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536583/
https://www.ncbi.nlm.nih.gov/pubmed/30848009
http://dx.doi.org/10.1111/cpr.12592

Ejemplares similares